DE69719360D1 - Zusammensetzungen und methoden zur steigerung der darmfunktion - Google Patents
Zusammensetzungen und methoden zur steigerung der darmfunktionInfo
- Publication number
- DE69719360D1 DE69719360D1 DE69719360T DE69719360T DE69719360D1 DE 69719360 D1 DE69719360 D1 DE 69719360D1 DE 69719360 T DE69719360 T DE 69719360T DE 69719360 T DE69719360 T DE 69719360T DE 69719360 D1 DE69719360 D1 DE 69719360D1
- Authority
- DE
- Germany
- Prior art keywords
- methods
- increasing
- glp
- compositions
- bowel function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000003871 intestinal function Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 abstract 3
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 abstract 3
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 abstract 3
- 239000000813 peptide hormone Substances 0.000 abstract 3
- 210000002429 large intestine Anatomy 0.000 abstract 2
- 210000000813 small intestine Anatomy 0.000 abstract 2
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 235000016709 nutrition Nutrition 0.000 abstract 1
- 208000030212 nutrition disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/763,177 US5952301A (en) | 1996-12-10 | 1996-12-10 | Compositions and methods for enhancing intestinal function |
| PCT/CA1997/000945 WO1998025644A1 (en) | 1996-12-10 | 1997-12-10 | Compositions and methods for enhancing intestinal function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69719360D1 true DE69719360D1 (de) | 2003-04-03 |
| DE69719360T2 DE69719360T2 (de) | 2003-12-04 |
Family
ID=25067085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69719360T Expired - Lifetime DE69719360T2 (de) | 1996-12-10 | 1997-12-10 | Zusammensetzungen und methoden zur steigerung der darmfunktion |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5952301A (de) |
| EP (1) | EP0944396B1 (de) |
| AT (1) | ATE233096T1 (de) |
| AU (1) | AU5220098A (de) |
| CA (1) | CA2274596C (de) |
| DE (1) | DE69719360T2 (de) |
| DK (1) | DK0944396T3 (de) |
| ES (1) | ES2193406T3 (de) |
| PT (1) | PT944396E (de) |
| WO (1) | WO1998025644A1 (de) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020025933A1 (en) * | 1996-08-30 | 2002-02-28 | Knudsen Liselotte Bjerre | GLP-2 derivatives |
| CA2236519C (en) | 1997-05-02 | 2011-09-13 | 1149336 Ontario Inc. | Methods of enhancing functioning of the large intestine |
| JP4699576B2 (ja) * | 1997-05-16 | 2011-06-15 | １１４９３３６ オンタリオ インコーポレーテッド | 胃腸管上部の機能を強化する方法 |
| DE04029691T1 (de) * | 1998-02-02 | 2007-11-08 | Trustees Of Tufts College, Medford | Verwendung von Dipetidylpeptidasehemmer zur Regulierung des Glukosemetabolismus |
| AU7421598A (en) * | 1998-05-11 | 1999-11-29 | 1149336 Ontario Inc. | Methods of enhancing functioning of the large intestine |
| WO2000010549A1 (en) * | 1998-08-21 | 2000-03-02 | Point Therapeutics, Inc. | Regulation of substrate activity |
| US6979697B1 (en) | 1998-08-21 | 2005-12-27 | Point Therapeutics, Inc. | Regulation of substrate activity |
| GB9906714D0 (en) | 1999-03-23 | 1999-05-19 | Ferring Bv | Compositions for improving fertility |
| GB9906715D0 (en) | 1999-03-23 | 1999-05-19 | Ferring Bv | Compositions for promoting growth |
| US6890904B1 (en) | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
| EP1806138A1 (de) * | 1999-05-25 | 2007-07-11 | Point Therapeutics, Inc. | Anti-tumor präparate enthaltend boroprolin verbindungen |
| EP1187619A1 (de) * | 1999-05-25 | 2002-03-20 | Point Therapeutics, Inc. | Anti-tumor präparate enthaltend boroprolin verbindungen |
| ATE381343T1 (de) * | 1999-11-03 | 2008-01-15 | Novo Nordisk As | Verwendung eines wachstumshormons oder eines wachstumshormon-sekretion fördernden mittels zur appetit-unterdrückung bzw. sättigungsinduktion |
| US6599882B1 (en) | 1999-11-05 | 2003-07-29 | Joseph A. Rogoff | Secretin and secretin pharmaceuticals for treating lactose intolerance |
| GB9930882D0 (en) * | 1999-12-30 | 2000-02-23 | Nps Allelix Corp | GLP-2 formulations |
| US7371721B2 (en) * | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
| DK1326630T3 (da) | 2000-09-18 | 2008-09-15 | Sanos Bioscience As | Anvendelse af GLP-2-peptider |
| US20070135345A1 (en) * | 2000-09-18 | 2007-06-14 | Henriksen Dennis B | Use of GLP-2 for the treatment or prevention, of bone-related disorders |
| US20080249016A1 (en) * | 2000-09-18 | 2008-10-09 | Sanos Bioscience A/S | Use of GLP-2 in a combination treatment for bone-related disorders |
| CA2436399A1 (en) * | 2001-02-16 | 2002-08-29 | Conjuchem Inc. | Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders |
| JP2005511636A (ja) * | 2001-11-26 | 2005-04-28 | トラスティーズ オブ タフツ カレッジ | 自己免疫疾患の治療方法及びそれに関する試薬 |
| AU2002357767C1 (en) * | 2001-11-26 | 2009-03-19 | Trustees Of Tufts College | Peptidomimetic inhibitors of post-proline cleaving enzymes |
| US20040038864A1 (en) * | 2002-06-27 | 2004-02-26 | Per Balschmidt | Use of dimethyl sulfone as isotonicity agent |
| US7411039B2 (en) * | 2002-10-14 | 2008-08-12 | Novo Nordisk A/S | GLP-2 compounds, formulations, and uses thereof |
| US20080026077A1 (en) * | 2002-11-12 | 2008-01-31 | John Hilfinger | Methods and compositions of gene delivery agents for systemic and local therapy |
| US20050026859A1 (en) * | 2002-11-12 | 2005-02-03 | John Hilfinger | Methods and compositions of gene delivery agents for systemic and local therapy |
| US7576121B2 (en) * | 2003-11-12 | 2009-08-18 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| AR046778A1 (es) * | 2003-11-12 | 2005-12-21 | Phenomix Corp | Compuestos heterociclicos de acido boronico. metodos de obtencion y composiciones farmaceuticas. |
| US7767828B2 (en) * | 2003-11-12 | 2010-08-03 | Phenomix Corporation | Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| US7317109B2 (en) * | 2003-11-12 | 2008-01-08 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| US20080269311A1 (en) * | 2004-07-14 | 2008-10-30 | Edwin Bernard Villhauer | Combination of Dpp-Iv Inhibitors and Compounds Modulating 5-Ht3 and/or 5-Ht4 Receptors |
| CA2607150C (en) * | 2005-05-04 | 2014-08-05 | Bjarne Due Larsen | Glucagon-like-peptide-2 (glp-2) analogues |
| US7825139B2 (en) * | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| KR101527233B1 (ko) | 2006-11-08 | 2015-06-08 | 질랜드 파마 에이/에스 | 선택적인 글루카곤 유사 펩티드-2(ｇｌｐ-2) 유사체 |
| US20110295151A1 (en) * | 2010-05-26 | 2011-12-01 | Bakos Gregory J | Enteroendocrine Manipulation for Metabolic Effect |
| CA2872315A1 (en) | 2012-05-03 | 2013-11-07 | Zealand Pharma A/S | Glucagon-like-peptide-2 (glp-2) analogues |
| ES2913946T3 (es) | 2013-07-08 | 2022-06-06 | The Univ Of Utah Research Foundation | Péptido y su uso en el tratamiento de trastornos inflamatorios |
| CN106167789B (zh) * | 2015-05-21 | 2020-08-04 | 中国科学院上海营养与健康研究所 | 低氧处理的间充质干细胞及其应用 |
| CN106589110B (zh) * | 2015-10-15 | 2020-01-17 | 上海迈迹生物医药科技有限公司 | 包含聚合物和glp-2衍生物的缀合物 |
| EP3551651B1 (de) | 2016-12-09 | 2024-03-06 | Zealand Pharma A/S | Acylierte glp-1/glp-2 duale agoniste |
| ES2894629T3 (es) | 2017-06-16 | 2022-02-15 | Zealand Pharma As | Pautas posológicas para la administración de análogos del péptido 2 similar al glucagón (GLP-2) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2174838T3 (es) * | 1991-10-07 | 2002-11-16 | Brigham & Womens Hospital | Metodo para aumentar la absorcion del intestino. |
| NZ260309A (en) * | 1992-06-08 | 1997-07-27 | Pharmacia Ab Substituted For K | Use of 1gf-2 for prevention or treatment of nutritional or gastrointestinal disorders and promoting neonatal growth |
| US5990077A (en) * | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| JP4148994B2 (ja) * | 1996-04-12 | 2008-09-10 | １１４９３３６ オンタリオ インコーポレイテッド | グルカゴン様ペプチド―２アナログ |
-
1996
- 1996-12-10 US US08/763,177 patent/US5952301A/en not_active Expired - Lifetime
-
1997
- 1997-12-10 CA CA002274596A patent/CA2274596C/en not_active Expired - Fee Related
- 1997-12-10 PT PT97946986T patent/PT944396E/pt unknown
- 1997-12-10 AT AT97946986T patent/ATE233096T1/de active
- 1997-12-10 DE DE69719360T patent/DE69719360T2/de not_active Expired - Lifetime
- 1997-12-10 EP EP97946986A patent/EP0944396B1/de not_active Expired - Lifetime
- 1997-12-10 DK DK97946986T patent/DK0944396T3/da active
- 1997-12-10 AU AU52200/98A patent/AU5220098A/en not_active Abandoned
- 1997-12-10 WO PCT/CA1997/000945 patent/WO1998025644A1/en not_active Ceased
- 1997-12-10 ES ES97946986T patent/ES2193406T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0944396B1 (de) | 2003-02-26 |
| ES2193406T3 (es) | 2003-11-01 |
| US5952301A (en) | 1999-09-14 |
| DK0944396T3 (da) | 2003-06-23 |
| CA2274596A1 (en) | 1998-06-18 |
| CA2274596C (en) | 2004-11-09 |
| AU5220098A (en) | 1998-07-03 |
| EP0944396A1 (de) | 1999-09-29 |
| WO1998025644A1 (en) | 1998-06-18 |
| ATE233096T1 (de) | 2003-03-15 |
| DE69719360T2 (de) | 2003-12-04 |
| PT944396E (pt) | 2003-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69719360D1 (de) | Zusammensetzungen und methoden zur steigerung der darmfunktion | |
| DK0981362T3 (da) | Anvendelse af GLP-2-agonister, der forbedrer funktionen af den øvre mavetarmkanal | |
| DE69736634D1 (de) | Antagonisten des intestinotrophen glp-2 peptides | |
| EP1231218A3 (de) | Peptid zur Appetitzügelung, dessen Zusammensetzungen und Verwendung | |
| DE69731373D1 (de) | Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen | |
| ID26984A (id) | Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda | |
| ATE410441T1 (de) | Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidinanalogen | |
| ATE288444T1 (de) | Dipeptide, die die ausschüttung von wachstumshormonen stimulieren | |
| WO1998033509A3 (en) | Useful properties of human lactoferrin and variants thereof | |
| MXPA05002991A (es) | Analogos de ghrh. | |
| BR9607336A (pt) | Composições de aminoácidos e utilidades das mesmas em nutrição clinica | |
| DE69919179D1 (de) | Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen | |
| ES2168457T3 (es) | Composiciones farmaceuticas que comprenden una superoxido dismutasa. | |
| ATE232700T1 (de) | Implantatkörper | |
| BR0111506A (pt) | Complexos de droga macromoleculares e composições contendo os mesmos | |
| DE69931482D1 (de) | Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen | |
| BR0213536A (pt) | Formulações de xarope de ribavirina | |
| PE20050665A1 (es) | ESTROGENOS SELECTIVOS DE 8ß-VINIL-ESTRA-1,3,5(10)-TRIEN-3,17ß-DIOL Y 17ß-FLUOR-9-VINIL-ESTRA-1,3,6(10)-TRIEN-3,16ALFA-DIOL | |
| GB9811221D0 (en) | Bacterial-pheromones and uses therefor | |
| DK1165102T3 (da) | Matrixproteinpræparater til podning i ikke-mineraliseret væv | |
| BR0109279A (pt) | Antagonistas de lhrh, sua preparação e aplicação como medicamento | |
| BG103905A (en) | New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine | |
| EP0917535A4 (de) | Neuroaktive peptide | |
| DE60030270D1 (de) | Fettsaure analoge zur diagnose von kranzarterie erkrankungen | |
| ATE279198T1 (de) | Kombinationen von endometrium schonenden gestagenen und endometrium atrophisierenden gestagenen mit estrogenen, bei der oralen empfängnisverhütung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |